[ad_1]
LONDON (Reuters) – A $165 million (119 million pounds) venture fund focused on tackling “superbugs” resistant to modern antibiotics has been launched to invest in small companies working on novel medicines.
[ad_2]
Source link
Novo Holdings launches $165 million 'superbug' drug venture fund
